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Introduction
The Q703K is a variant of NLRP3 gene has an unknown
pathogenetic significance. It, has been considered to be
a clinically unremarkable polymorphism, due to its pre-
sence in 12-20% of general population. However, a recent
study has shown that carriers of the Q703K display an
higher secretion of IL-1b, thus suggesting a possible
pathogenic role of this variant.
Objectives
To analyse the prevalence of Q703K mutation in
patients screened for suspected CAPS and to describe
the clinical and biomarkers findings of patients carrying
of this mutation.
Methods
From 2002 the molecular analysis of the NLRP3 gene was
performed in 615 patients with a clinical history sugges-
tive for CAPS in two different centers (pediatric vs adult).
In consideration of the prevalence of this mutation in the
general population, 90 healthy individuals were also
analyzed for the same mutation.
Results
The Q703K mutation was found in the 35 screened
patients (pediatric 17 vs adult 18, with the mean age was
23,7 years, range 3-64). The mean age at onset was 21,5
years (range 0,5-57). Thirty patients were heterozygous
for theQ703K mutation only. Two pts displayed other
mutations of NLRP3 gene (M604I in one CINCA and
D303N and V198M in a MWS). Three patients display
a monoallelic variant of MEFV gene (R202Q, V726A,
D303N). The mean follow-up was 2,5 years (range 0,2-8).
The prevalent clinical features were fever and urticarial
rash (23 pts), urticarial rash without fever (6 pts) and per-
iodic fever only (6 pts). The main clinical manifestations
and treatment are reported in the table. According to the
judgment of the physician in charge, a CAPS-like pheno-
type was observed in 23 patients (66%). In 12 pts (34%)
an alternative diagnosis was pointed out (mainly undiffer-
entiated periodic fever). The frequency of the variant
Q703K in normal controls was 2,22%.
Conclusion
The Q703K mutation can be associated to a mild CAPS-
like phenotype. Most of the patients do not require
anti-IL1 treatment and respond satisfactory to steroid
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on demand. Even if this variant can be found in patients
with a other conditions, the prevalence in patients with
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